Information on research, events, activities, and news from the T1D community across Canada.
We are incredibly grateful to our partners, and the entire T1D community for their commitment and support as we work together to move type 1 diabetes research forward faster than ever.
This month, we wanted to recognize some of our amazing monthly donors and thank them for their support. Their stories will help you understand why they’re In to End Diabetes.
The type 1 diabetes (T1D) community has always embraced new technology – with insulin pumps, continuous glucose monitors (CGMs), flash glucose monitors (FGMs), and a variety of T1D-focused apps rapidly becoming essential tools for many people. It’s no surprise, then, that the T1D communi...
Type 1 diabetes (T1D) and type 2 diabetes may have little in common, but a new research study has revealed that a drug used to treat the latter could also benefit individuals living with T1D.
Imagine being treated for one disease only to learn that form of therapy may lead to another grave condition. New research has revealed that some patients are diagnosed with autoimmune disorders following cancer immunotherapy.
We’re very excited to announce the winners of the Boston Pizza Foundation Future Prospects Award Program for JDRF! Through the generous support of Boston Pizza Foundation Future Prospects, the Program is awarding $5,000 dollars each for a total of $105,000 to help students living with type 1 d...
What if people at risk of developing type 1 diabetes (T1D) could curb the progression of the disease by a couple of years?
Beta cells normally produce insulin, a chemical messenger that helps move sugar from food sources into cells throughout the body, which use it for fuel to stay alive.
Insulin has been the subject of many news stories recently as the high cost of insulin and other drugs has led to two US federal initiatives aimed at allowing the bulk importation of lower cost Canadian drugs.
JDRF has written to the BC government asking that all BC residents living with type 1 diabetes have affordable access to the Medtronic MiniMed 670G and the Tandem t:slim X2 by adding them to the province’s list of approved Tier 2 devices under the province’s insulin program.